Gilead Sciences, Inc. (GILD)

Market Cap	192.28B +59.1%
Revenue (ttm)	29.44B +2.4%
Net Income	8.51B +1,672.9%
EPS	6.78 +1,684.2%
Shares Out	1.24B
PE Ratio	22.86
Forward PE	17.77
Dividend	$3.28 (2.12%)
Ex-Dividend Date	Mar 13, 2026

Volume	6,754,484
Open	151.89
Previous Close	151.81
Day's Range	151.46 - 156.95
52-Week Range	93.37 - 157.29
Beta	0.39
Analysts	Strong Buy
Price Target	141.56 (-8.66%)
Earnings Date	Feb 10, 2026

About GILD

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• IPO Date: Jan 22, 1992
• Employees: 17,600
• Stock Exchange: NASDAQ
• Ticker Symbol: GILD
• Website: https://www.gilead.com

Financial Performance

In 2025, Gilead Sciences's revenue was $29.44 billion, an increase of 2.40% compared to the previous year's $28.75 billion. Earnings were $8.51 billion, an increase of 1672.92%.

Analyst Summary

According to 18 analysts, the average rating for GILD stock is "Strong Buy." The 12-month stock price target is $141.56, which is a decrease of -8.66% from the latest price.

Price Target

$141.56

(-8.66% downside)

Analyst Consensus: Strong Buy